With so many stocks trading under $1, it’s difficult to keep track of companies with real potential.
Their low price tag suggests accessibility, and the potential for outsized returns can be alluring. But beneath that, there’s often volatility, limited analyst coverage, and heightened risk.
We’ll showcase the nine best stocks under $1 across various industries, each offering growth pathways without relying on speculative hype.
TL;DR: Top Stocks Under $1 To Watch Out
- GEE Group Inc. (NYSEAMERICAN: JOB) – Staffing services with expanding AI-driven recruiting.
- Resolution Minerals Ltd (OTC: RLMLF) – Idaho explorer targeting gold, antimony, tungsten.
- Virax Biolabs Group Ltd (NASDAQ: VRAX) – Immune diagnostics and T-cell response testing.
- Plus Therapeutics, Inc. (NASDAQ: PSTV) – Radiotherapeutics advancing brain and CNS cancer care.
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) – TCR-based immunotherapy with FDA-approved treatment.
- Enveric Biosciences (NASDAQ: ENVB) – Non-hallucinogenic neuroplastogens for mental health therapy.
- MariMed Inc. (OTCMKTS: MRMD) – Multi-state cannabis operator with strong retail brands.
- Kobrea Exploration Corp. (OTC: KBXFF) – Junior copper explorer with Argentine land package.
- CISO Global (NASDAQ: CISO) – Cybersecurity solutions with AI and managed services.
3 Best Stocks Under $1 with Potential
GEE Group Inc. (NYSEAMERICAN: JOB)
Overview
With roots stretching back to 1893, GEE Group is not a flashy startup but a seasoned staffing and recruiting firm built on decades of on-the-ground experience.
Today, it stands as a collection of established brands working across industries, from IT and engineering to finance, accounting, and even healthcare.
Its team-based approach puts people first, placing qualified professionals into roles that align with both employer needs and candidate careers.
Operating from over 30 offices across 15 U.S. states, it has grown steadily by nurturing multiple staffing divisions, from contract hires to direct placements, while staying grounded in the basics of matching talent with opportunity.
Growth Catalysts
What’s interesting about GEE right now is its shift from legacy staffing to something more tech-savvy and future-proof.
Having shed its industrial staffing division, the company is doubling down on professional staffing and even tapping into AI tools to streamline recruiting and back-end operations.
To that end, there’s momentum in how it’s redesigning its workflows and plugging into efficiencies that could matter for years to come.
Plus, the acquisition of Hornet Staffing earlier this year brings access to Fortune 1000 clients and offshore recruiting capabilities.
That’s meaningful traction for a low-price stock.
Risks
That said, the staffing industry is hardly immune to macroeconomic slowdowns. When hiring freezes happen, and especially when projects get paused, GEE feels it.
We’ve seen a dip in revenue this year, and while margins have held up thanks to direct hire work, volatility remains.
And even the AI story comes with caveats: a heavy shift toward automation risks pushing away clients who value hands-on, relationship-based recruiting.
It’s a delicate balance—tech innovation can be a lifeline, but only if adopted thoughtfully.
Conclusion
There’s a grounded sensibility to the way GEE Group is evolving.
It’s not chasing fads or speculative headlines; instead, it’s focusing on efficiency, better client targeting, and digital enablement.
Sure, the near-term staffing market might wobble, but if the company continues integrating AI and building deeper client relationships, it could emerge from the cycle stronger, and smarter.
If you value a blend of old-school staffing know-how and emerging tech focus, this pick offers that dual narrative.
Resolution Minerals Ltd (OTC: RLMLF)
Overview
This small-cap explorer holds a significant asset in Idaho, the Horse Heaven project.
It spans over 5,600 hectares and shares a boundary with the well-known Stibnite project, one of the only domestic sources of antimony, gold, and tungsten.
The site includes two promising target zones, where historical surface mining and shallow drilling confirmed the presence of gold, antimony, tungsten, and silver.
Rather than chasing hype, the company is methodically walking its ground with fresh exploration tools and a strategic U.S. market listing.
Growth Catalysts
First, the commencement of diamond-core drilling at Golden Gate marks a real step forward, explorers have identified visible scheelite (a tungsten-bearing mineral) in multiple holes, a sign of tungsten presence that wasn’t previously assayed.
Beyond the rockwork, listing on the OTCQB has expanded investor access and credibility, offering visibility to U.S. capital markets, a critical move for a company betting on defense and critical minerals interest.
The project’s location is another plus: sitting adjacent to a flagship antimony-gold-tungsten development gives it context and immediate geological comparability.
Lastly, although a proposed A$225 million acquisition by a peer didn’t go through, that offer serves as a tangible benchmark of the asset’s perceived potential.
Risks
As with any junior explorer, much depends on what’s beneath the surface.
Visible minerals are encouraging, but assay results must validate economic grades. Development will require continued capital, and any new funding or listings risk stretching patience if execution stalls.
The OTCQB upgrade improves exposure, but liquidity and reporting standards still trail behind main exchanges.
Volatility in critical minerals markets also looms—shifts in demand or policy could quickly affect investor interest.
Conclusion
Here’s a story grounded in location, geology, and execution readiness.
If U.S. critical mineral supply paths matter to you, this junior offers strategic positioning within a real development corridor.
Everything now hinges on drilling results and follow-through, but the setup feels meaningful and rooted in substance, not speculation.
Virax Biolabs Group Ltd (NASDAQ: VRAX)
Overview
Virax Biolabs operates in the biotech space with a precise focus on immune diagnostics.
The company produces a suite of in-vitro diagnostic test kits, spanning everything from infectious disease panels to women’s health, oncology, and veterinary needs, all under its ViraxClear and ViraxVet brands.
Beyond that, it’s developing the ViraxImmune™ platform, a T-cell–based immune profiling tool that aims to assess how individuals respond to viral threats and post-viral conditions, including long COVID and other immune-related syndromes.
With laboratories in the UK and a growing footprint in the U.S., the team blends research expertise with real-world product applications.
Growth Catalysts
A few key drivers stand out. First, the clinical rollout has gained momentum., Virax initiated a U.K. study assessing T-cell dysfunction in post-acute infection syndromes, enrolling up to 160 participants, with completion expected by early 2026.
Second, regulatory momentum is building. The company plans to submit for a formal FDA pre-submission (Q-submission), aimed at preparing the Immune Profiling Platform for U.S. clearance.
Third, its global reach is expanding. It just added Emory University as its clinical partner in the U.S. to support validation efforts, alongside broad distribution agreements in Europe and GCC, boosting product exposure and credibility.
Risks
Despite these advances, risk remains. The Nasdaq has issued a notice regarding the stock price falling below minimum thresholds, putting compliance in the crosshairs, potentially affecting listing status if not addressed.
Clinical development is far from assured; meaningful results in 2026 are required to sustain momentum.
Operating in micro-cap biotech, funding sustainability and execution become major pressure points, especially as clinical validation and regulatory pursuit both demand capital.
Conclusion
The story here revolves around smart positioning: immune health diagnostics grounded in an underserved clinical niche, with growing clinical and regulatory infrastructure.
For investors drawn to foundational innovations in T-cell testing and long-COVID diagnostics, this remains a name to watch.
However, the company comes with typical biotech caveats, and success depends on trial validation, regulatory navigation, and execution discipline.
If you value that blend of science-driven solutions and careful development, this could be a quietly placed speculative play
Best Biotech Stocks Under $1
Plus Therapeutics, Inc. (NASDAQ: PSTV)
Overview
Stepping beyond conventional radiation therapy, this Houston-based clinical-stage biotech innovates with targeted radiotherapeutics for central nervous system cancers.
Its flagship therapy, REYOBIQ™, harnesses nanoliposome technology carrying Rhenium-186, aiming to deliver precise radiation directly to tumors like recurrent glioblastoma and leptomeningeal metastases.
This approach aims to preserve healthy tissue, often a limitation with traditional radiation, by staying focused on the diseased area with a single, powerful dose.
Plus Therapeutics also runs CNSide Diagnostics, a subsidiary offering a cerebrospinal fluid assay to detect and monitor cancer cells in the central nervous system, now launching regionally.
Growth Catalysts
Recent clinical developments are encouraging. Data presented in mid-2025 showed that REYOBIQ™ delivered a strong response in patients with leptomeningeal metastases, with measures of disease control exceeding typical expectations and a manageable safety profile.
These results have set the stage for a phase 2 optimization trial, following FDA signals to move forward with dosing refinement.
On the diagnostic front, CNSide assays are now being rolled out in Texas at leading cancer centers, enabling more precise patient management.
Plus Therapeutics also secured an FDA clearance to launch a pediatric brain cancer trial, backed by Department of Defense funding.
Structurally, the company reworked its capital raise to eliminate dilutive terms, boosting shareholder value without sharing the upside via warrants.
Risks
Even with meaningful trial results, the biotech journey remains far from easy. Future clinical milestones will require consistent execution, and success hinges on funding through development stages while avoiding unnecessary dilution.
Although NASDAQ compliance is solid for now, the risk of volatility remains typical for clinical-stage names.
Diagnostic uptake could face barriers if clinical adoption isn’t smooth or faster to scale.
In essence, long-term value depends on combining positive trial data with savvy financial and market execution.
Conclusion
Here lies a biotech playing to its strengths, radiotherapeutics tailored for previously underserved brain-cancer patients paired with diagnostic tools to support treatment monitoring.
The path ahead isn’t smooth, but the company’s clinical focus, renewed structural footing, and commercialization setup provide a clear narrative.
If you believe in precision oncology where spatial targeting plays a major role, this remains a high-conviction pick, with caveats tied to outcomes and execution pace.
Adaptimmune Therapeutics plc (NASDAQ: ADAP)
Overview
Adaptimmune Therapeutics is a biotech with a mission that’s science-forward and patient-focused, pioneering T-cell receptor (TCR) therapies specifically for solid tumors.
Based in both the U.K. and Philadelphia, this company made history by winning the first FDA approval for a TCR cell therapy in a solid tumor, a mark of credibility that won’t fade.
Its legacy is grounded in deep immunotherapy expertise rooted in university research and years of clinical work.
The firm remains committed to making single-dose, targeted cell therapies that reprogram a patient’s own immune system to zero in on tumors, especially difficult-to-treat ones.
Growth Catalysts
A key driver is their recent FDA-approved product, Tecelra, targeting synovial sarcoma, a rare but aggressive cancer.
Approval alone is rare in the TCR space and doubles as real-world validation of their technology.
Even better, they’ve struck a strategic deal to sell Tecelra and related therapies to a pharmaceutical firm, freeing up cash to redirect into newer programs like those targeting various cancers that show promise in the pipeline
Meanwhile, late-stage trials for afami-cel and lete-cel continue to make progress. The company is streamlining its focus, clearing debt, and redirecting resources toward therapies that could define its next chapter.
Risks
Solid-tumor T-cell therapies are complex, and clinical and regulatory hurdles remain high.
Tecelra approval is a win, but maintaining momentum hinges on the success of follow-up trials.
Long-term impact depends on execution, and funding remains tight, especially now that legacy therapies are being transitioned away.
The company carries a high-volatility profile common to micro-cap biotechs, and steep dilution risk is always lurking if funding stalls or trials stumble.
Conclusion
Adaptimmune is making steps into real-world change, marked by a pioneering TCR therapy on the market and a sharpening focus on its next wave of candidates.
If you believe the future of cancer treatment lies in precision cell therapy, this firm gives you a seat at that table.
But, to see if the promise pans out, you’ll want to watch trial updates, capital strategy, and how the next-gen pipeline shapes up.
Enveric Biosciences (NASDAQ: ENVB)
Overview
Enveric is a biotech working at the intersection of innovation and practicality.
Instead of chasing psychedelic headlines, the focus has been on developing small-molecule neuroplastogens; compounds designed to promote brain adaptability without hallucinogenic effects.
The centerpiece is EB-003, a non-hallucinogenic molecule that targets both 5-HT1A and 5-HT2A receptors, potentially reshaping treatment for depression, anxiety, PTSD, and other conditions where patients have few reliable options.
Based on recent filings and their “Psybrary™” platform, Enveric continues building a pipeline of thoughtfully engineered small molecules with intent and purpose.
Growth Catalysts
There’s clear forward motion. EB-003 has shown encouraging preclinical results, including favorable oral availability, brain exposure, and dual-receptor engagement, proof points for mental health efficacy potential.
Patent milestones underscore progress: the company secured intellectual property protection for EB-003 and an entire series of mescaline-derived analogs, positioning itself as a thought leader in non-hallucinogenic neuroplastogens.
On the business front, Enveric has expanded its pipeline via licensing agreements for cannabinoid-COX-2 conjugates aimed at joint health, creating additional diversity in its scientific portfolio.
Participation in major biotech conferences and investor roadshows further signals active outreach and execution readiness.
Risks
Still, it’s early days. All therapeutic candidates remain in preclinical phases, and success hinges on achieving IND clearance and then navigating clinical trials, a long road with many hurdles.
The niche appeal of non-hallucinogenic neuroplastogens is promising, but mainstream clinical acceptance isn’t guaranteed.
As a development-stage outfit, funding must be managed carefully to bridge trials without excessive dilution.
Conclusion
This is biotech with quiet ambition: scientific rigor married with patient-centric innovation.
Enveric is actively building neurotherapeutics guided by targeted receptor action and patent grounding.
If you believe in a future where mental health treatment leverages brain plasticity without the flash, this is a name worth keeping on your watch list.
But keep your expectations grounded: development paths are long, results uncertain, and execution must remain disciplined.
Best Marijuana Stocks Under $1
MariMed Inc. (OTCMKTS: MRMD)
Overview
MariMed is a well-established multi-state cannabis operator with a genuinely integrated model—from cultivation and processing to retail.
It’s built around award-winning brands like Betty’s Eddies, Bubby’s Baked, Vibations, and Nature’s Heritage. Each brand speaks to real consumer preferences instead of just flashing novelty.
Its network spans several U.S. states, and the company consistently builds beyond state lines through licensing, management services, and strategic partnerships.
What stands out is its seed-to-sale continuity, handling everything in-house to ensure quality and consistency across regulated cannabis markets.
Growth Catalysts
Several developments underscore its thoughtful expansion.
Early in 2025, it completed the acquisition of a leading Delaware operator, integrating cultivation, processing, and dispensary locations, a fully vertical entry that was almost pre-approved by permitting authorities.
This strengthened its position as Delaware gears up for adult-use legalization, potentially unlocking substantial local sales.
Around the same time, a licensing deal in Maine widened access to its Betty’s Eddies product, bringing that retail favorite into medical channels through a well-positioned partner.
And in mid-2025, a new arrangement took its brands into Pennsylvania, tapping into a top medical marijuana market.
Finally, it quietly launched wholesale operations in Missouri, adding yet another distribution frontier to its portfolio without overextending attention.
Risks
But execution must remain disciplined. Integration across different states brings regulatory complexity, ranging from licensing to compliance.
Managing each brand consistently requires strong operational oversight. Also, political risk remains, cannabis regulations could shift, and federal uncertainty still looms.
While its business model strengthens visibility, OTC listing limits transparency compared to major exchanges.
All these factors mean execution missteps can hurt, especially in contested or quickly evolving state markets.
Conclusion
Here’s a cannabis company that’s expanding with prudence and precision. Its core strength lies in proven branding, self-managed vertical operations, and calculated market growth via acquisitions and partnerships.
If you’re watching multi-state cannabis plays grounded in operations and strategy, not hype, this name is quietly moving in the right direction. Just watch how it navigates regional compliance and scales brand familiarity over the coming year.
Best Metal Exploration Stocks Under $1
Kobrea Exploration Corp. (OTC: KBXFF)
Overview
Kobrea Exploration is a junior miner focused on uncovering copper-rich porphyry systems across its Western Malargüe land package in Argentina.
Spanning over 73,000 hectares in Mendoza Province, the company holds earn-in rights to seven contiguous projects rich in geological promise.
Highlights include El Perdido and Elena, where extensive hydrothermal alteration and mineralized breccia zones suggest copper, possibly with gold and molybdenum, could be present at depth.
Field teams have already mapped breccia structures as wide as 1,700 by 250 meters, indicative of major porphyry-style systems, while airborne geophysical surveys aim to reveal the underlying alteration footprint.
Growth Catalysts
The exploration story here is built on both scale and momentum. Kobrea has completed the next staged option payment, affirming its commitment to the Western Malargüe properties.
On the ground, the focus is intense: geological mapping, sampling, a sizable airborne magnetic-radiometric survey, and permitting for drill access roads are all active.
The goal is to test the El Perdido zone first, but the broader land package offers multiple targets ripe for discovery.
Backed by seasoned geologists, including a new chief geologist with decades of porphyry experience, the company is methodically pushing toward defining a legitimate copper system.
Risks
Even promising geology doesn’t guarantee success. Until drilling produces solid assay results, exploration remains speculative.
The path forward depends heavily on continued funding, further option payments and drilling campaigns require capital and careful timing.
Being listed on OTCQB keeps it visible to U.S. investors, but liquidity remains limited.
And while the copper outlook is positive globally, any shifts in mining sentiment or financing conditions could slow momentum for junior exploration players.
Conclusion
Here’s an explorer whose value lies in its location, land scale, and disciplined build-out.
With multi-target potential, initial permitting progress, and field detail in hand, it’s a name for investors comfortable with high-risk, high-upside opportunities, especially in critical metals exploration.
Watch the drilling developments closely; if the models hold, this is one story that could deliver material upside grounded in geology, not just buzz.
Cheap Stocks to Buy Now Under $1 Dollar
CISO Global (NASDAQ: CISO)
Overview
In an age when small and midsize organizations often lag behind on cybersecurity, this company steps in with a fully integrated, AI-powered defense and compliance platform.
Based in Arizona, it stretches its services across the U.S., Chile, and other regions, offering more than just software.
Clients also receive managed cybersecurity, virtual chief information security officer (vCISO) support, compliance assurance, and ongoing security training.
Their approach aims to simplify a complex landscape and solve cybersecurity not as a silo, but as a woven element of company culture.
They consolidate tools and services so businesses can invest confidently and securely in their growth.
Growth Catalysts
A few moves stand out as particularly strategic.
First, they unveiled CyberSimple, a service that bundles AI-driven endpoint protection with affordable cyber-insurance packages made specifically for small businesses, an elegant way to offer both defense and financial backup in one.
They also tailored their CHECKLIGHT® platform for sectors like professional employment organizations and financial management companies, proving flexibility in application.
More broadly, they’ve built momentum through a string of acquisitions, bringing specialist talent together to boost both service depth and recurring revenue.
A completed SOC 2 Type II audit adds a trust layer for clients, while improved gross margins suggest operational tightening.
Their adjusted capital structure, including converting debt into preferred equity, also showcases an eye toward financial prudence.
Risks
Despite these positives, caution is warranted. The NASDAQ spotlight comes with volatility and the ongoing pressure to expand revenue, particularly in a competitive cybersecurity market.
While automation solves one problem, ramping it without losing personalized service is a delicate balance.
Also, pairing insurance with protection means they inherit underwriting risk, claims or coverage issues could create unexpected liabilities.
Finally, their OTC-to-NASDAQ journey may bring improved visibility, but maintaining consistent compliance and liquidity remains a long-term challenge.
Conclusion
Here’s a firm that feels more thoughtful than flashy, helping less-resourced businesses build resilient security while offering financial peace of mind.
Their AI-driven protection, combined with insurance and an expanding service portfolio, reflects an evolving cybersecurity model for the mid-market.
Still, in a fast-shifting landscape where execution and discipline matter, success depends on proving delivery, growing trust, and managing risk tightly.
Should I Buy Stocks Under $1?
Investing in sub‑$1 stocks might serve some readers well, but it deserves caution. The appeal lies in low capital outlay and the possibility of earning multi‑bag gains if a company advances.
However, these names often come with significant volatility, liquidity challenges, and questionable funding.
They may be favored by speculative traders, but investors seeking long‑term stability should tread carefully.
If you prioritize disciplined research, understand business models, and can handle rapid price swings, some of these companies may fit your risk profile. Otherwise, it’s wise to look at more established equities.
Stocks Under $1: Features to Look for
Keep these tips in mind the next time you set out to purchase a stock under $1.
Company Background
Before even looking at charts or stock price, it’s important to ask whether the business behind the ticker is real and credible.
A legitimate under-$1 stock should have a definable business model, operating history, and a clear sector focus.
For example, staffing firms, biotech developers, cannabis operators, or junior miners all operate in industries with specific and transparent metrics.
Investors should look for signs of consistency, like company longevity, leadership experience, and a verifiable presence in its field. Thinly veiled shell companies or firms with vague business descriptions are red flags.
Financial Information
Even if the stock price is low, fundamentals still matter. Review whether the company has any revenue, what its main expenses are, and how much cash it keeps on hand.
Biotech firms may not yet generate revenue, but can still demonstrate value through clinical pipelines and grants.
Resource explorers may rely on staged financing, but should provide clear exploration results.
What matters is the presence of reliable reporting and disclosures. If a company struggles to file regular financials, that’s a warning sign.
High Daily Trading Volume
Liquidity separates tradeable opportunities from dead money. Stocks under $1 that trade with regular volume give investors a fair chance to enter and exit positions without excessive slippage.
Consistent daily activity also suggests ongoing interest from the market, even if speculative.
On the other hand, stocks that barely trade for days at a time can trap investors, leaving them unable to sell when conditions change. Always check the average daily volume before considering an entry.
News Catalysts
Price movement in low-priced stocks is often tied to fresh developments. For biotech, it may be clinical trial updates or FDA approvals.
For exploration companies, drilling results and project acquisitions often move the needle.
For cannabis firms, regulatory changes or new state licenses are common sparks.
A reliable under-$1 stock will have identifiable catalysts on the horizon, whether in the form of partnerships, product launches, or expansions. If no such events exist, the stock may drift with little momentum.
Trades on a Major Exchange
Finally, exchange status adds a layer of credibility. Nasdaq- and NYSE-listed sub-$1 stocks must meet stricter reporting, compliance, and governance standards compared to firms that only trade over the counter.
While not every OTC company is illegitimate, exchange-listed names generally provide more transparency and better liquidity.
Investors seeking to minimize risk should focus on these exchange-traded options, as they offer a safer entry point in an already speculative corner of the market.
Best Stocks Under $1: Final Thoughts
Trading stocks of companies with a small market cap comes with a lot of risks, and proper market timing is key.
Day traders that can effectively wield volatility could have an opportunity to see solid gains.
That being said, there are stocks under $1 that could be fantastic long positions.
Across sectors like staffing, biotech, mental health therapeutics, cannabis, metals, and cyber, we’ve featured firms with tangible business elements and long‑term potential.
Avoid emotional buys, anchor your analysis in fundamentals, and always respect your risk limits. With thoughtful selection, these low‑price names can offer compelling paths—but they must be researched, monitored, and understood.
Stocks Under $1 FAQ
What Are Penny Stocks and Why Are They Considered High Risk?
Penny stocks are shares of small companies that trade for less than $5 per share, often under $1.
They are considered high risk due to their low market capitalization and low volume stocks, which can lead to significant price volatility and potential manipulation.
Additionally, these companies may have uncertain financial stability, making thorough research crucial before buying.
Which Is the Best Penny Stock?
There’s no clear-cut answer for which penny stock is best for you, as this is entirely dependent on your trading style and investment objective.
That said, energy securities like Gevo, Inc. could be a good place to start your search, as energy has been seen as a relatively stable investment.
What Are Some Good 1 Dollar Stocks?
GEE Group stands out for its reach across multiple markets in a space that will never go away.
In addition, MariMed is always a good $1 stock to keep your eyes on as regulations change towards cannabis use.
Why Are Low Volume Penny Stocks Risky?
Low volume stocks, often found among penny stocks, can be risky because they have fewer buyers and sellers, making it harder to trade shares without affecting the price.
This lack of liquidity can lead to significant price changes with even small trades, increasing the investment risk.
Stocks under $1 can be a good place to start because prices are so low.
However, it’s helpful to understand the market’s volatility and how penny stocks can rise or fall very quickly.
Long-term stocks could be a good entry point, as they are expected to increase slowly over time.
What Are Some Strategies for Trading Penny Stocks?
Successful trading strategies for penny stocks include setting clear entry and exit points, using stop-loss orders to mitigate risk, and diversifying investments to spread risk across multiple stocks.
It’s also beneficial to stay updated with market news and trends that could impact the stocks’ performance, ensuring informed trading decisions.
Can Penny Stocks Make You Rich?
It’s unlikely you’ll find a penny stock that will grow to the size of Amazon, but they are potentially good sources of income.
Like all other stocks, research is required before investing in a penny stock.
Consider the company’s financial stability and growth prospects before investing.
Check out our list of the best stocks to buy under $5 for more penny stocks worth considering.
Tags:
